Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma in Europe

In advanced cutaneous T-cell lymphoma (CTCL), allogeneic stem cell transplant is the only curative option, but many patients are ineligible and relapse after systemic therapy, requiring retreatment with prior therapies. Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody drug conjugated with monomethyl auristatin E, is approved by the European Medicines Agency for adult patients with CD30+ CTCL after ≥1 prior systemic therapy. We present efficacy and safety findings of BV retreatment from a multi-center, retrospective real-world study of 26 patients with CTCL conducted in Europe (NCT05886478). Overall response rate was higher after first BV treatment versus BV retreatment (88.5% vs. 54.2%), but progression-free survival was longer after retreatment (9.8 months, 95% confidence interval [CI]: 5.1-11.1) versus first treatment (8.1 months, 95% CI: 6.7-11.0). Adverse events including peripheral neuropathy were more common at first treatment. These results suggest that BV retreatment is effective and generally well tolerated for patients with CTCL.